Last edition
News about "American Academy of Neurology (AAN)"
FDA Accepts Ionis' Zilganersen NDA for Priority Review in AxD
Ionis’ zilganersen NDA for Alexander disease has been accepted by the FDA for Priority Review, with a PDUFA target action date set for 22nd September, 2026, marking a key regulatory milestone for the potential treatment.
American Academy Of Neurology (AAN) | 24/03/2026 | By News Bureau
Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial
Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.
American Academy Of Neurology (AAN) | 02/03/2026 | By News Bureau | 118
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy